Every employer realizes that protecting employees’ health is paramount right now, but with so many uncertainties they need confidence that their testing strategy is optimized for success. We take a close look at parameters to consider in building an effective, sustainable COVID-19 employee testing plan.
BioAgilytix’s CLIA Laboratory Director, Natalie Smith, outlines the differences between CLIA, CAP & COLA regulations & accreditations, and what they mean for laboratory testing quality.
In our recruitment process we are often asked by those coming from pharma & biotech careers, “what’s a day in the life like at a CRO?” Who better to ask than our own team members who have made the career transition themselves? We start the discussion with Dr. Jim McNally.
The concept of using pre-existing immunogenicity as an exclusion criteria for gene therapy clinical trials is changing. BioAgilytix’s Chief Scientific Officer, Dr. Jim McNally, explores why.
Bruton’s tyrosine kinase (BTK) is a key regulator of B cell receptor and Fc receptor signaling and is a proven therapeutic target for autoimmune diseases. In recent months, BTK inhibitors are also being deployed in the fight against COVID-19.
We recently sat down with Dr. Jim McNally for a Q&A to hear his "Behind the Science" perspectives on the industry and where he thinks BioAgilytix brings the most value to pharma & biotech customers.
We've compiled a guide to the presentations & forums our BioAgilytix team members will be participating in throughout the 2020 WRIB Virtual Meeting so you can join in the conversations too.
Did you know that our new General Manager, Europe, Dr. Frank Horling, was a client of BioAgilytix before joining our team? We asked him to share his perspectives on what it was like to be a BioAgilytix customer as well as what motivated him to join our lab in Hamburg, Germany.
As COVID-19 lockdowns begin to lift, the question is: where do we go from here? BioAgilytix is in a highly unique position to help both biopharma & companies with testing to keep their work on track: whether that means progressing clinical trials or reopening their businesses and offices safely.
Dr. Jeff Patrick answers questions on how BioAgilytix translated a diagnostic virus neutralization method to a quantitative relative potency assay for an anti-viral antibody.
Services
Platforms